tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA

IDEAYA Biosciences (IDYA) AI Stock Analysis

Compare
558 Followers

Top Page

ID

IDEAYA Biosciences

(NASDAQ:IDYA)

Rating:53Neutral
Price Target:
$22.00
▼(-0.45%Downside)
The overall stock score of 53 reflects significant financial performance challenges, as evidenced by declining revenues and net losses, despite a strong equity position. Technical analysis shows moderate positive momentum, but valuation is unattractive due to negative profitability. Without earnings call data or impactful corporate events, these factors dominate the assessment.
Positive Factors
Clinical Trial Outcomes
Data for the daro+crizo combination so far look superior to the standard of care.
Market Opportunities
Registry data suggest that the market opportunity for HLA-negative could be 3-4 times relative to HLA-positive, indicating a potentially larger market than previously expected.
Pipeline Updates
The company's updates from its early pipeline should offer upside in the next 12-18 months.
Negative Factors
Approval Challenges
An accelerated approval opportunity, which the company previously highlighted as a possibility, is unlikely.
Investor Concerns
Investor focus on OS is unlikely to be fully addressed at the upcoming disclosure.
Market Uncertainty
Investors are understandably cautious on the de-risking potential of progression-free survival data on the overall survival full approval endpoint, indicating some uncertainty in the market.

IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)

IDEAYA Biosciences Business Overview & Revenue Model

Company DescriptionIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
How the Company Makes MoneyIDEAYA Biosciences generates revenue primarily through collaboration and license agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales if the partnered drugs successfully reach the market. For instance, IDEAYA may collaborate with larger pharmaceutical companies to co-develop and commercialize its drug candidates, leveraging their partner's resources and expertise in exchange for shared financial benefits. The company's revenue is also supported by research grants and funding aimed at advancing its pipeline of potential cancer therapies. However, as a clinical-stage biotech company, significant revenue generation is generally contingent on the successful development, approval, and commercialization of its drug candidates.

IDEAYA Biosciences Financial Statement Overview

Summary
IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.
Income Statement
42
Neutral
The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.
Balance Sheet
55
Neutral
IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.
Cash Flow
48
Neutral
Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.00M7.00M23.39M50.93M27.94M19.54M
Gross Profit5.26M3.17M19.38M48.83M26.22M-20.16M
EBITDA-357.95M-326.98M-130.42M-60.40M-48.54M-33.96M
Net Income-306.31M-274.48M-112.96M-54.81M-47.53M-32.27M
Balance Sheet
Total Assets1.10B1.12B649.32M387.97M381.35M298.27M
Cash, Cash Equivalents and Short-Term Investments692.51M676.32M525.11M373.15M368.06M283.58M
Total Debt25.97M19.17M2.87M3.48M5.18M6.72M
Total Liabilities76.51M64.94M28.23M387.97M381.35M298.27M
Stockholders Equity1.02B1.06B621.09M349.45M301.51M198.27M
Cash Flow
Free Cash Flow-267.98M-251.44M-117.59M-90.62M-58.42M54.97M
Operating Cash Flow-264.11M-247.58M-115.22M-87.17M-55.78M55.46M
Investing Cash Flow-68.77M-502.56M-158.46M-33.40M-69.67M-146.24M
Financing Cash Flow354.58M677.55M362.72M97.17M145.45M128.75M

IDEAYA Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.10
Price Trends
50DMA
20.22
Positive
100DMA
19.35
Positive
200DMA
23.55
Negative
Market Momentum
MACD
0.43
Positive
RSI
58.42
Neutral
STOCH
51.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 22.1 is above the 20-day moving average (MA) of 21.82, above the 50-day MA of 20.22, and below the 200-day MA of 23.55, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 51.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Risk Analysis

IDEAYA Biosciences disclosed 77 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IDEAYA Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$3.14B-32.17%-25.85%-23.89%
58
Neutral
$1.66B-5.78%25.50%64.63%
58
Neutral
$2.05B-16.57%
53
Neutral
$1.94B-31.34%-54.85%-79.25%
52
Neutral
$2.01B-38.04%-82.38%-164.76%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
42
Neutral
$1.48B-69.30%-68.13%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDYA
IDEAYA Biosciences
22.10
-17.41
-44.06%
ETNB
89bio
10.16
2.26
28.61%
BEAM
Beam Therapeutics
20.01
-3.84
-16.10%
KYMR
Kymera Therapeutics
44.79
12.83
40.14%
IMCR
Immunocore Holdings
33.02
-4.44
-11.85%
CGON
CG Oncology, Inc.
26.90
-5.14
-16.04%

IDEAYA Biosciences Corporate Events

Executive/Board Changes
IDEAYA Biosciences Appoints New Chief Financial Officer
Neutral
Jun 27, 2025

On June 26, 2025, IDEAYA Biosciences appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. This strategic appointment may influence the company’s financial management and operational strategies.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Executive/Board ChangesShareholder Meetings
IDEAYA Biosciences Holds Annual Stockholders Meeting
Neutral
Jun 24, 2025

On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025